Free Trial

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 2.6%

Recursion Pharmaceuticals logo with Medical background

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) dropped 2.6% on Tuesday . The stock traded as low as $7.17 and last traded at $7.21. Approximately 1,887,338 shares changed hands during mid-day trading, a decline of 69% from the average daily volume of 6,175,219 shares. The stock had previously closed at $7.40.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a "buy" rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, June 25th.

Read Our Latest Analysis on Recursion Pharmaceuticals

Recursion Pharmaceuticals Stock Up 0.5 %

The company has a market capitalization of $1.77 billion, a P/E ratio of -4.65 and a beta of 0.83. The company's 50-day simple moving average is $8.77 and its 200 day simple moving average is $9.83.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.04. The company had revenue of $13.80 million during the quarter, compared to the consensus estimate of $11.10 million. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The company's revenue for the quarter was up 14.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.34) earnings per share. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.


Insiders Place Their Bets

In other news, COO Tina Marriott sold 6,000 shares of the business's stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $7.21, for a total value of $43,260.00. Following the completion of the sale, the chief operating officer now directly owns 535,457 shares in the company, valued at $3,860,644.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Michael Secora sold 23,124 shares of the company's stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $7.58, for a total transaction of $175,279.92. Following the completion of the transaction, the chief financial officer now directly owns 1,231,055 shares in the company, valued at approximately $9,331,396.90. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the company's stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $7.21, for a total transaction of $43,260.00. Following the transaction, the chief operating officer now owns 535,457 shares of the company's stock, valued at $3,860,644.97. The disclosure for this sale can be found here. Insiders sold 207,359 shares of company stock valued at $1,704,435 over the last ninety days. Corporate insiders own 15.75% of the company's stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of RXRX. ARK Investment Management LLC grew its holdings in Recursion Pharmaceuticals by 200.4% during the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company's stock worth $203,651,000 after acquiring an additional 13,777,689 shares during the last quarter. Vanguard Group Inc. lifted its position in Recursion Pharmaceuticals by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company's stock valued at $159,667,000 after purchasing an additional 349,554 shares during the period. Mubadala Investment Co PJSC acquired a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $128,041,000. Kinnevik AB publ lifted its position in Recursion Pharmaceuticals by 14.4% during the 2nd quarter. Kinnevik AB publ now owns 11,905,668 shares of the company's stock valued at $89,293,000 after purchasing an additional 1,500,000 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in Recursion Pharmaceuticals by 12.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company's stock valued at $103,317,000 after purchasing an additional 1,159,023 shares during the period. Institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Featured Stories

→ [URGENT] Altcoin Winning Picks (From Crypto Swap Profits) (Ad)

Should you invest $1,000 in Recursion Pharmaceuticals right now?

Before you consider Recursion Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.

While Recursion Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Opportunities Arise as Stock Market Rotates from Big Tech

Opportunities Arise as Stock Market Rotates from Big Tech

Discover how the great stock rotation is shaking up the market and what it means for your investments, including the companies poised for growth.

Related Videos

3 Top Market Leaders Splitting Their Stocks
CPI News Breakdown: Key Market Moves to Follow
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines